Thyroid Cancer Clinical Trial
— MAeSTro?Official title:
Study Protocol of Extended Multicenter Prospective Cohort Study of Active Surveillance on Papillary Thyroid Carcinoma (MAeSTroâ…ˇ)
This study is an observational cohort study targeting patients with low-risk Papillary thyroid cancer who opted for active surveillance or immediate surgery based on a sufficient understanding of the treatment options. The primary objective of the study is to evaluate progression free survival of the patients with low-risk Papillary thyroid cancer who choose active surveillance, in other words, to observe the natural course of low-risk Papillary thyroid cancer.
Status | Not yet recruiting |
Enrollment | 499 |
Est. completion date | December 31, 2032 |
Est. primary completion date | December 31, 2029 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - subjects over 18 years old with a thyroid nodule of = 1.5 cm in maximum diameter and a Bethesda category V or VI diagnosis on cytopathology - subjects without high-risk features, including lymph node (LN) metastasis, distant metastasis, signs or symptoms of invasion to the recurrent laryngeal nerve or trachea, Poorly differentiated cancer or variant with a poor prognosis, such as the tall cell, diffuse sclerosing, columnar cell, or solid variants. Exclusion Criteria: - subjects who are unable or unwilling to attend regular follow-ups.. - subjects with a diagnosis of benign, atypia of undetermined significance, suspicious for follicular neoplasm, or follicular neoplasm (Bethesda category II, III, or IV) based on Fine needle aspiration or, or benign, indeterminate by core needle biopsy. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | National Cancer Center | Goyang-si | |
Korea, Republic of | Seoul National University Bundang Hospital | Seongnam | |
Korea, Republic of | Seoul National University Hospital | Seoul | |
Korea, Republic of | SMC-SNU Boramae Medical Center | Seoul |
Lead Sponsor | Collaborator |
---|---|
National Cancer Center, Korea | Seoul National University Bundang Hospital, Seoul National University Hospital, SMG-SNU Boramae Medical Center |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Progression free survival of the patients with low-risk Papillary Thyroid Cancer who choose Active Surveillance | Disease progression in the following criteria: (1) a size increase of =3 mm in maximum diameter; (2) a cytopathological diagnosis of a new thyroid cancer lesion; (3) a cytopathological diagnosis of a cervical LN metastasis; or (4) clinical or radiological suspicion of a distant metastasis. | At 5years, 10years | |
Secondary | Disease progression | Defined as follows: primary tumor growth >13 mm in largest diameter or primary tumor 20mm in largest diameter in the active surveillance group, or new metastatic disease or newly diagnosed thyroid cancer in the active surveillance group and surgical group | At 5years, 10years | |
Secondary | Rate of Participants in the Active Surveillance Group that change to surgery without disease progression | The rate of participants in the active surveillance group who cross over to thyroidectomy without disease progression during follow-up will be reported. | At 5years, 10years | |
Secondary | Comparison of Quality of Life between the Active Surveillance group and immediate surgery group | The Quality of Life - Thyroid (QOL-Thyroid) questionnaire was 30 items. These are assigned to four scales, each reflecting an aspect of QoL. Physical well-being is measured with two items and 13 questions, psychological well-being with 13 items and 22 questions, social concerns with eight items and 14 questions, and spiritual well-being with seven items and questions. Response options range from '0 = worst outcome' to '10 = best outcome' on an ordinal 11-point scale. | every six months for the first two years, every six month to twelve months thereafter, for up to 10years | |
Secondary | Measure of Anxiety and Depression | Hospital Anxiety and Depression Scale is a measure developed to measure anxiety and depression symptoms in general hospital visiting patients. it is consists of a total of 14 questions, 7 questions related to anxiety and 7 questions related to depression, and the higher the score, the higher the level of anxiety and depression. | every six months for the first two years, every six month to twelve months thereafter, for up to 10years | |
Secondary | Measure of Satisfaction with the treatment | minimum score 0, maximum score 40, where a lower number indicates a worse outcome | every six months for the first two years, every six month to twelve months thereafter, for up to 10years | |
Secondary | Factors influencing patients' decisions regarding disease management | Participants will be asked the reason for choosing Active surveillance or surgery decision is complete for the disease management plan. Each participant will be asked, in a semi-structured interview question, to explain the reason why the disease management strategy that was chosen. | every six months for the first two years, every six month to twelve months thereafter, for up to 10years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05774535 -
Prospective, Observational Study on the Carotid Intima-media Thickness in Patients Undergoing Thyroid Surgery
|
||
Withdrawn |
NCT04224792 -
Effects of Exercise Training on Fatigue in Thyroid Cancer Survivors
|
N/A | |
Completed |
NCT01728623 -
A Study of E7080 in Subjects With Advanced Thyroid Cancer
|
Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT02911155 -
Cancer and Other Disease Risks in U.S. Nuclear Medicine Technologists
|
||
Recruiting |
NCT05025046 -
NGS-based Thyroscan Genomic Classifier in the Diagnosis of Thyroid Nodules
|
||
Not yet recruiting |
NCT03978351 -
The Role of Midkine in Diagnosis of Thyroid Cancer
|
||
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Terminated |
NCT02628535 -
Safety Study of MGD009 in B7-H3-expressing Tumors
|
Phase 1 | |
Withdrawn |
NCT01994200 -
Developing and Implementing an Interdisciplinary Team-Based Care Approach (ITCA-ThyCa) for Thyroid Cancer Patients
|
Phase 1/Phase 2 | |
Completed |
NCT02375451 -
Effect of Childhood Radioiodine Therapy on Salivary Function
|
N/A | |
Terminated |
NCT01403324 -
Comparison of Dosimetry After rhTSH or Withdrawal of Thyroid Hormone in Metastatic or Locally Advanced Thyroid Cancer
|
N/A | |
Completed |
NCT00970359 -
Reacquisition of Radioactive Iodine (RAI) Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment With the Selective MEK Inhibitor AZD6244
|
N/A | |
Completed |
NCT00439478 -
Dental Safety Profile of High-Dose Radioiodine Therapy
|
Phase 4 | |
Completed |
NCT00223158 -
Evaluation Study of L-T3 Utility in the Follow-up of Patients With Thyroid Cancer
|
N/A | |
Active, not recruiting |
NCT04544111 -
PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer
|
Phase 2 | |
Completed |
NCT04876287 -
Salivary dysfuncTion After Radioiodine Treatment
|
||
Recruiting |
NCT06073223 -
Intervention to Decrease Overtreatment of Patients With Low-risk Thyroid Cancer
|
N/A | |
Recruiting |
NCT06037174 -
Comparison of Quality of Life in Patients With Differentiated Thyroid Carcinoma Undergoing Different Surgery
|
||
Recruiting |
NCT04952493 -
Anlotinib or Penpulimab in Combination With RAI for DTC
|
Phase 2 |